Interleukin-12  ||| S:0 E:15 ||| NNP
gene  ||| S:15 E:20 ||| NN
polymorphisim  ||| S:20 E:34 ||| NN
in  ||| S:34 E:37 ||| IN
patients  ||| S:37 E:46 ||| NNS
with  ||| S:46 E:51 ||| IN
giant  ||| S:51 E:57 ||| JJ
cell  ||| S:57 E:62 ||| NN
arteritis ||| S:62 E:71 ||| NN
,  ||| S:71 E:73 ||| ,
polymyalgia  ||| S:73 E:85 ||| JJ
rheumatica  ||| S:85 E:96 ||| NN
and  ||| S:96 E:100 ||| CC
elderly-onset  ||| S:100 E:114 ||| JJ
rheumatoid  ||| S:114 E:125 ||| NNS
arthritis  ||| S:125 E:135 ||| VBP
The  ||| S:135 E:139 ||| DT
cytokine  ||| S:139 E:148 ||| JJ
profile  ||| S:148 E:156 ||| NN
suggests  ||| S:156 E:165 ||| VBZ
that  ||| S:165 E:170 ||| DT
giant  ||| S:170 E:176 ||| JJ
cell  ||| S:176 E:181 ||| NN
arteritis  ||| S:181 E:191 ||| NNS
( ||| S:191 E:192 ||| -LRB-
GCA ||| S:192 E:195 ||| NNP
)  ||| S:195 E:197 ||| -RRB-
is  ||| S:197 E:200 ||| VBZ
a  ||| S:200 E:202 ||| DT
Th1-driven  ||| S:202 E:213 ||| JJ
disease ||| S:213 E:220 ||| NN
,  ||| S:220 E:222 ||| ,
in  ||| S:222 E:225 ||| IN
which  ||| S:225 E:231 ||| WDT
local  ||| S:231 E:237 ||| JJ
IFN-gamma  ||| S:237 E:247 ||| NN
plays  ||| S:247 E:253 ||| VBZ
a  ||| S:253 E:255 ||| DT
critical  ||| S:255 E:264 ||| JJ
role  ||| S:264 E:269 ||| NN
in  ||| S:269 E:272 ||| IN
the  ||| S:272 E:276 ||| DT
development  ||| S:276 E:288 ||| NN
of  ||| S:288 E:291 ||| IN
a  ||| S:291 E:293 ||| DT
systemic  ||| S:293 E:302 ||| JJ
arteritis ||| S:302 E:311 ||| NN
.  ||| S:311 E:313 ||| .
IL-12  ||| S:313 E:319 ||| NNP
is  ||| S:319 E:322 ||| VBZ
a  ||| S:322 E:324 ||| DT
potent  ||| S:324 E:331 ||| JJ
inducer  ||| S:331 E:339 ||| NN
of  ||| S:339 E:342 ||| IN
IFN-gamma  ||| S:342 E:352 ||| JJ
and  ||| S:352 E:356 ||| CC
is  ||| S:356 E:359 ||| VBZ
critically  ||| S:359 E:370 ||| RB
involved  ||| S:370 E:379 ||| VBN
in  ||| S:379 E:382 ||| IN
biasing  ||| S:382 E:390 ||| VBG
an  ||| S:390 E:393 ||| DT
immune  ||| S:393 E:400 ||| JJ
response  ||| S:400 E:409 ||| NN
towards  ||| S:409 E:417 ||| IN
a  ||| S:417 E:419 ||| DT
Th1  ||| S:419 E:423 ||| JJ
pathway ||| S:423 E:430 ||| NN
.  ||| S:430 E:432 ||| .
The  ||| S:432 E:436 ||| DT
purpose  ||| S:436 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
this  ||| S:447 E:452 ||| DT
study  ||| S:452 E:458 ||| NN
was  ||| S:458 E:462 ||| VBD
to  ||| S:462 E:465 ||| TO
investigate  ||| S:465 E:477 ||| VB
whether  ||| S:477 E:485 ||| IN
there  ||| S:485 E:491 ||| EX
was  ||| S:491 E:495 ||| VBD
an  ||| S:495 E:498 ||| DT
association  ||| S:498 E:510 ||| NN
between  ||| S:510 E:518 ||| IN
an  ||| S:518 E:521 ||| DT
IL-12  ||| S:521 E:527 ||| JJ
gene  ||| S:527 E:532 ||| NN
polymorphism  ||| S:532 E:545 ||| NNS
( ||| S:545 E:546 ||| -LRB-
-1188  ||| S:546 E:552 ||| NNP
A ||| S:552 E:553 ||| NNP
/ ||| S:553 E:554 ||| NNP
C  ||| S:554 E:556 ||| NNP
3UTR ||| S:556 E:560 ||| NNP
)  ||| S:560 E:562 ||| -RRB-
and  ||| S:562 E:566 ||| CC
disease  ||| S:566 E:574 ||| NN
susceptibility  ||| S:574 E:589 ||| NN
for  ||| S:589 E:593 ||| IN
GCA  ||| S:593 E:597 ||| NNP
and  ||| S:597 E:601 ||| CC
two  ||| S:601 E:605 ||| CD
other  ||| S:605 E:611 ||| JJ
age-related  ||| S:611 E:623 ||| JJ
inflammatory  ||| S:623 E:636 ||| JJ
conditions ||| S:636 E:646 ||| NNS
,  ||| S:646 E:648 ||| ,
such  ||| S:648 E:653 ||| JJ
as  ||| S:653 E:656 ||| IN
polymyalgia  ||| S:656 E:668 ||| JJ
rheumatica  ||| S:668 E:679 ||| NNS
( ||| S:679 E:680 ||| -LRB-
PMR ||| S:680 E:683 ||| NNP
)  ||| S:683 E:685 ||| -RRB-
and  ||| S:685 E:689 ||| CC
elderly-onset  ||| S:689 E:703 ||| JJ
rheumatoid  ||| S:703 E:714 ||| JJ
arthritis  ||| S:714 E:724 ||| NN
( ||| S:724 E:725 ||| -LRB-
EORA ||| S:725 E:729 ||| NNP
) ||| S:729 E:730 ||| -RRB-
.  ||| S:730 E:732 ||| .
Furthermore ||| S:732 E:743 ||| RB
,  ||| S:743 E:745 ||| ,
we  ||| S:745 E:748 ||| PRP
attempted  ||| S:748 E:758 ||| VBD
to  ||| S:758 E:761 ||| TO
correlate  ||| S:761 E:771 ||| VB
such  ||| S:771 E:776 ||| JJ
polymorphism  ||| S:776 E:789 ||| NN
with  ||| S:789 E:794 ||| IN
in  ||| S:794 E:797 ||| IN
vitro  ||| S:797 E:803 ||| CD
IL-12  ||| S:803 E:809 ||| CD
production ||| S:809 E:819 ||| NN
.  ||| S:819 E:821 ||| .
We  ||| S:821 E:824 ||| PRP
analyzed  ||| S:824 E:833 ||| VBD
genotypes  ||| S:833 E:843 ||| VBN
at  ||| S:843 E:846 ||| IN
-1188  ||| S:846 E:852 ||| CD
in  ||| S:852 E:855 ||| IN
the  ||| S:855 E:859 ||| DT
3UTR  ||| S:859 E:864 ||| NN
of  ||| S:864 E:867 ||| IN
the  ||| S:867 E:871 ||| DT
IL-12  ||| S:871 E:877 ||| JJ
promoter  ||| S:877 E:886 ||| NN
by  ||| S:886 E:889 ||| IN
PCR-RFLP  ||| S:889 E:898 ||| JJ
in  ||| S:898 E:901 ||| IN
68  ||| S:901 E:904 ||| CD
GCA ||| S:904 E:907 ||| NNP
,  ||| S:907 E:909 ||| ,
138  ||| S:909 E:913 ||| CD
PMR ||| S:913 E:916 ||| NNP
,  ||| S:916 E:918 ||| ,
and  ||| S:918 E:922 ||| CC
72  ||| S:922 E:925 ||| CD
EORA  ||| S:925 E:930 ||| NN
patients  ||| S:930 E:939 ||| NNS
as  ||| S:939 E:942 ||| IN
well  ||| S:942 E:947 ||| RB
as  ||| S:947 E:950 ||| RB
in  ||| S:950 E:953 ||| IN
465  ||| S:953 E:957 ||| CD
healthy  ||| S:957 E:965 ||| JJ
controls  ||| S:965 E:974 ||| NNS
( ||| S:974 E:975 ||| -LRB-
HC ||| S:975 E:977 ||| NNP
) ||| S:977 E:978 ||| -RRB-
.  ||| S:978 E:980 ||| .
IL-12p70  ||| S:980 E:989 ||| NNP
levels  ||| S:989 E:996 ||| NNS
in  ||| S:996 E:999 ||| IN
culture  ||| S:999 E:1007 ||| NN
supernatants  ||| S:1007 E:1020 ||| NN
after  ||| S:1020 E:1026 ||| IN
stimulation  ||| S:1026 E:1038 ||| NN
with  ||| S:1038 E:1043 ||| IN
PMA+Ionomycin  ||| S:1043 E:1057 ||| NNP
was  ||| S:1057 E:1061 ||| VBD
assessed  ||| S:1061 E:1070 ||| VBN
by  ||| S:1070 E:1073 ||| IN
ELISA ||| S:1073 E:1078 ||| NNP
.  ||| S:1078 E:1080 ||| .
All  ||| S:1080 E:1084 ||| DT
groups  ||| S:1084 E:1091 ||| NNS
were  ||| S:1091 E:1096 ||| VBD
in  ||| S:1096 E:1099 ||| IN
Hardy-Weinberg  ||| S:1099 E:1114 ||| JJ
equilibrium ||| S:1114 E:1125 ||| NN
.  ||| S:1125 E:1127 ||| .
Allelic  ||| S:1127 E:1135 ||| NNP
and  ||| S:1135 E:1139 ||| CC
gen-omic  ||| S:1139 E:1148 ||| JJ
distribution  ||| S:1148 E:1161 ||| NN
was  ||| S:1161 E:1165 ||| VBD
not  ||| S:1165 E:1169 ||| RB
significantly  ||| S:1169 E:1183 ||| RB
different  ||| S:1183 E:1193 ||| JJ
among  ||| S:1193 E:1199 ||| IN
the  ||| S:1199 E:1203 ||| DT
study  ||| S:1203 E:1209 ||| NN
groups ||| S:1209 E:1215 ||| NNS
.  ||| S:1215 E:1217 ||| .
None  ||| S:1217 E:1222 ||| NN
of  ||| S:1222 E:1225 ||| IN
the  ||| S:1225 E:1229 ||| DT
genetic  ||| S:1229 E:1237 ||| JJ
variants  ||| S:1237 E:1246 ||| NN
was  ||| S:1246 E:1250 ||| VBD
associated  ||| S:1250 E:1261 ||| VBN
with  ||| S:1261 E:1266 ||| IN
disease  ||| S:1266 E:1274 ||| NN
severity ||| S:1274 E:1282 ||| NN
.  ||| S:1282 E:1284 ||| .
Although  ||| S:1284 E:1293 ||| IN
the  ||| S:1293 E:1297 ||| DT
differences  ||| S:1297 E:1309 ||| NNS
were  ||| S:1309 E:1314 ||| VBD
not  ||| S:1314 E:1318 ||| RB
statistically  ||| S:1318 E:1332 ||| RB
significant ||| S:1332 E:1343 ||| JJ
,  ||| S:1343 E:1345 ||| ,
HC  ||| S:1345 E:1348 ||| NNP
genotypes  ||| S:1348 E:1358 ||| NN
were  ||| S:1358 E:1363 ||| VBD
associated  ||| S:1363 E:1374 ||| VBN
with  ||| S:1374 E:1379 ||| IN
distinct  ||| S:1379 E:1388 ||| JJ
IL-12  ||| S:1388 E:1394 ||| CD
p70  ||| S:1394 E:1398 ||| CD
production ||| S:1398 E:1408 ||| NN
.  ||| S:1408 E:1410 ||| .
The  ||| S:1410 E:1414 ||| DT
IL-12  ||| S:1414 E:1420 ||| NNP
( ||| S:1420 E:1421 ||| -LRB-
-1188  ||| S:1421 E:1427 ||| NNP
A ||| S:1427 E:1428 ||| NNP
/ ||| S:1428 E:1429 ||| NNP
C  ||| S:1429 E:1431 ||| NNP
3UTR ||| S:1431 E:1435 ||| NNP
)  ||| S:1435 E:1437 ||| -RRB-
gene  ||| S:1437 E:1442 ||| NN
polymorphism  ||| S:1442 E:1455 ||| NN
is  ||| S:1455 E:1458 ||| VBZ
not  ||| S:1458 E:1462 ||| RB
associated  ||| S:1462 E:1473 ||| VBN
with  ||| S:1473 E:1478 ||| IN
disease  ||| S:1478 E:1486 ||| NN
susceptibility  ||| S:1486 E:1501 ||| NNS
or  ||| S:1501 E:1504 ||| CC
severity  ||| S:1504 E:1513 ||| NN
in  ||| S:1513 E:1516 ||| IN
three  ||| S:1516 E:1522 ||| CD
age-related  ||| S:1522 E:1534 ||| JJ
chronic  ||| S:1534 E:1542 ||| JJ
inflammatory  ||| S:1542 E:1555 ||| JJ
syndromes ||| S:1555 E:1564 ||| NN
.  ||| S:1564 E:1566 ||| .
The  ||| S:1566 E:1570 ||| DT
production  ||| S:1570 E:1581 ||| NN
of  ||| S:1581 E:1584 ||| IN
IL-12  ||| S:1584 E:1590 ||| NNP
p70  ||| S:1590 E:1594 ||| NNP
is  ||| S:1594 E:1597 ||| VBZ
dependent  ||| S:1597 E:1607 ||| JJ
on  ||| S:1607 E:1610 ||| IN
the  ||| S:1610 E:1614 ||| DT
genetic  ||| S:1614 E:1622 ||| JJ
background  ||| S:1622 E:1633 ||| NN
in  ||| S:1633 E:1636 ||| IN
HC ||| S:1636 E:1638 ||| NNP
,  ||| S:1638 E:1640 ||| ,
although  ||| S:1640 E:1649 ||| IN
in  ||| S:1649 E:1652 ||| IN
patients  ||| S:1652 E:1661 ||| NNS
such  ||| S:1661 E:1666 ||| JJ
association  ||| S:1666 E:1678 ||| NN
may  ||| S:1678 E:1682 ||| MD
be  ||| S:1682 E:1685 ||| VB
biased  ||| S:1685 E:1692 ||| VBN
by  ||| S:1692 E:1695 ||| IN
other  ||| S:1695 E:1701 ||| JJ
unknown  ||| S:1701 E:1709 ||| JJ
factors ||| S:1709 E:1716 ||| NNS
.  ||| S:1716 E:1718 ||| .
